Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03487549 · ClinicalTrials.gov registry record · Phase 2
Cantharidin and Occlusion in Verruca Epithelium
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT03487549 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT03487549, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.
Interventions
- COMBINATION_PRODUCT VP-102 Cantharidin topical film forming solution
- COMBINATION_PRODUCT VP-102 Cantharidin, topical film forming solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03487549
The ClinicalTrials.gov registry entry for NCT03487549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VP-102 Cantharidin topical film forming solution is the first listed.
NCT03487549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03487549 about?
NCT03487549 is a clinical study titled "Cantharidin and Occlusion in Verruca Epithelium". This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.
What is the current status of trial NCT03487549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2018-03-27. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03487549?
The interventions under investigation include: VP-102 Cantharidin topical film forming solution (COMBINATION_PRODUCT), VP-102 Cantharidin, topical film forming solution (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03487549?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.